Literature DB >> 15683135

Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results.

Oscar Arias-Carrión1, Eric Murillo-Rodriguez, Man Xu, Carlos Blanco-Centurion, Rene Drucker-Colín, Priyattam J Shiromani.   

Abstract

STUDY
OBJECTIVES: The sleep disorder narcolepsy is now considered a neurodegenerative disease because there is a massive loss of neurons containing the neuropeptide, hypocretin, and because narcoleptic patients have very low cerebrospinal fluid levels of hypocretin. Transplants of various cell types have been used to induce recovery in a variety of neurodegenerative animal models. In models such as Parkinson disease, cell survival has been shown to be small but satisfactory. Currently, there are no data indicating whether hypocretin neurons can survive when grafted into host tissue. Here we examined the survival of hypocretin-containing neurons grafted into the pontine reticular formation, a region traditionally regarded to be key for rapid eye movement sleep generation.
DESIGN: In 2 experiments, a suspension of cells from the posterior hypothalamus of 8- to 10-day old rat pups was injected into the pons (midline, at the level of the locus coeruleus) of adult rats. Control rats received cells from the cerebellum, tissue that is devoid of hypocretin neurons. In the first experiment (n = 33), the adult rats were sacrificed 1, 3, 6, 12, 24, or 36 days after transplant, and cryostat-cut coronal sections of the brainstem were examined for presence of hypocretin-immunoreactive neurons. In the second experiment (n = 9), the transplant medium was modified to include agents that stimulate cell growth, and recipient rats were sacrificed 9, 12, and 36 days after receiving the graft. SETTINGS: Basic neuroscience research laboratory. MEASUREMENTS AND
RESULTS: In the first experiment, clearly defined hypocretin-immunoreactive containing somata and varicosities were visible in pons of rats sacrificed 1 day after grafting of posterior hypothalamic cells but not in rats receiving cerebellum tissue. The hypocretin-immunoreactive somata were not visible in rats sacrificed at 12, 24, or 36 days, indicating that the neurons had died. However, in the second experiment, where enriched transplant medium was used, clearly defined hypocretin-immunoreactive somata with processes and varicosities were present in the graft zone 36 days after implant. These somata were similar in size and appearance to adult rat hypocretin-immunoreactive neurons.
CONCLUSIONS: These results indicate that hypocretin neurons obtained from rat pups can be grafted into a host brain, and efforts should be made to increase survival of these neurons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15683135      PMCID: PMC1201562          DOI: 10.1093/sleep/27.8.1465

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  38 in total

1.  Behavioral and morphological studies of fetal neural transplants into SCN-lesioned rats.

Authors:  R Aguilar-Roblero; R Drucker-Colín; R Y Moore
Journal:  Chronobiol Int       Date:  1992-08       Impact factor: 2.877

Review 2.  Different neuronal phenotypes in the lateral hypothalamus and their role in sleep and wakefulness.

Authors:  Dmitry Gerashchenko; Priyattam J Shiromani
Journal:  Mol Neurobiol       Date:  2004-02       Impact factor: 5.590

3.  Quantitation of fiber growth in transplanted central monoamine neurons.

Authors:  A Seiger; L Olson
Journal:  Cell Tissue Res       Date:  1977-04-20       Impact factor: 5.249

4.  Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants.

Authors:  A Björklund; U Stenevi
Journal:  Brain Res       Date:  1979-11-30       Impact factor: 3.252

Review 5.  Intracerebral neural implants: neuronal replacement and reconstruction of damaged circuitries.

Authors:  A Björklund; U Stenevi
Journal:  Annu Rev Neurosci       Date:  1984       Impact factor: 12.449

6.  Fetal suprachiasmatic nucleus transplants: diurnal rhythm recovery of lesioned rats.

Authors:  R Drucker-Colín; R Aguilar-Roblero; F García-Hernández; F Fernández-Cancino; F Bermudez Rattoni
Journal:  Brain Res       Date:  1984-10-08       Impact factor: 3.252

7.  Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system.

Authors:  M J Perlow; W J Freed; B J Hoffer; A Seiger; L Olson; R J Wyatt
Journal:  Science       Date:  1979-05-11       Impact factor: 47.728

8.  Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice.

Authors:  Michihiro Mieda; Jon T Willie; Junko Hara; Christopher M Sinton; Takeshi Sakurai; Masashi Yanagisawa
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-16       Impact factor: 11.205

Review 9.  Cell transplantation for Parkinson's disease.

Authors:  Ben Roitberg; Klaudia Urbaniak; Marina Emborg
Journal:  Neurol Res       Date:  2004-06       Impact factor: 2.448

10.  Relationship between CSF hypocretin levels and hypocretin neuronal loss.

Authors:  Dmitry Gerashchenko; Eric Murillo-Rodriguez; Ling Lin; Man Xu; Laura Hallett; Seiji Nishino; Emmanuel Mignot; Priyattam J Shiromani
Journal:  Exp Neurol       Date:  2003-12       Impact factor: 5.330

View more
  10 in total

Review 1.  Control of sleep and wakefulness.

Authors:  Ritchie E Brown; Radhika Basheer; James T McKenna; Robert E Strecker; Robert W McCarley
Journal:  Physiol Rev       Date:  2012-07       Impact factor: 37.312

2.  Recent advances in the treatment of narcolepsy.

Authors:  Nobuhide Hirai; Seiji Nishino
Journal:  Curr Treat Options Neurol       Date:  2011-10       Impact factor: 3.598

Review 3.  Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights.

Authors:  Cayde Ritchie; Masashi Okuro; Takashi Kanbayashi; Seiji Nishino
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

4.  The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats.

Authors:  S Zhang; L Lin; S Kaur; S Thankachan; C Blanco-Centurion; M Yanagisawa; E Mignot; P J Shiromani
Journal:  Neuroscience       Date:  2007-07-06       Impact factor: 3.590

5.  Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice.

Authors:  Meng Liu; Stephen Thankachan; Satvinder Kaur; Suraiya Begum; Carlos Blanco-Centurion; Takeshi Sakurai; Masashi Yanagisawa; Rachael Neve; Priyattam J Shiromani
Journal:  Eur J Neurosci       Date:  2008-10       Impact factor: 3.386

6.  Narcolepsy and orexins: an example of progress in sleep research.

Authors:  Alberto K De la Herrán-Arita; Magdalena Guerra-Crespo; René Drucker-Colín
Journal:  Front Neurol       Date:  2011-04-18       Impact factor: 4.003

Review 7.  New developments in the management of narcolepsy.

Authors:  Vivien C Abad; Christian Guilleminault
Journal:  Nat Sci Sleep       Date:  2017-03-03

Review 8.  Cataplexy--clinical aspects, pathophysiology and management strategy.

Authors:  Yves Dauvilliers; Jerry M Siegel; Regis Lopez; Zoltan A Torontali; John H Peever
Journal:  Nat Rev Neurol       Date:  2014-06-03       Impact factor: 42.937

9.  Narcolepsy: current treatment options and future approaches.

Authors:  Michel Billiard
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

10.  Effects of hypocretin/orexin cell transplantation on narcoleptic-like sleep behavior in rats.

Authors:  Oscar Arias-Carrión; Eric Murillo-Rodríguez
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.